Key result
The ELECTRA pilot study is a rationale and design paper describing a planned randomized trial of 50 AMI patients comparing 60 mg vs 90 mg b.i.d. ticagrelor; no clinical results are reported.
Why the study?
Does a reduced maintenance dose of ticagrelor (60 mg b.i.d.) provide equally effective platelet inhibition compared to the standard dose (90 mg b.i.d.) in stable patients 1 month after AMI?
Population
50 patients with acute myocardial infarction treated with percutaneous coronary intervention, stable at Day…
Comparison
Ticagrelor 60 mg twice daily from Day 30 to Day… vs Ticagrelor 90 mg twice daily from Day 30 to Day…
Design
RCT, 1:1 ratio, open-label
Follow-up
Until Day 45 post-AMI (15 days post-randomization)
Authors
Loading...
Leaves ticagrelor 90 mg b.i.d. standard 1 month post-AMI; planned 50-patient pilot RCT will test platelet inhibition equivalence.
RCT (n=50)
Open-label
1:1
No
Does a reduced maintenance dose of ticagrelor (60 mg b.i.d.) provide equally effective platelet inhibition compared to the standard dose (90 mg b.i.d.) in stable patients 1 month after AMI?
The ELECTRA pilot study is designed to evaluate whether de-escalating ticagrelor to 60 mg twice daily at 30 days post-AMI maintains adequate platelet inhibition compared to the standard 90 mg twice daily dose.
Kubica et al. (2017) conducted an RCT in Acute myocardial infarction (AMI) (n=50). Ticagrelor vs. Ticagrelor 90 mg b.i.d. was evaluated on Platelet function (VASP assay and multiple electrode aggregometry) and pharmacokinetics. The ELECTRA pilot study is a rationale and design paper describing a planned randomized trial of 50 AMI patients comparing 60 mg vs 90 mg b.i.d. ticagrelor; no clinical results are reported.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: